Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
China Pharmaceutical University is managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners, meaning every pending case is being reviewed by a different individual. This distribution of actions to examiners suggests that the university's pharmaceutical portfolio is being evaluated through 5 different sets of professional eyes, which may lead to varied prosecution outcomes.
The 5 pending actions are spread across 3 distinct art units. This distribution indicates that the university's research in Biotechnology & Pharmaceuticals is diverse enough to fall under 3 different specialized groups within the patent office. Navigating 3 distinct art units requires a strategy that accounts for the specific examination cultures and prior art expertise of each unit.
REBECCA L ANDERSON is the busiest examiner for this portfolio, currently overseeing 1 pending office action. Since 1 is the maximum number of actions assigned to any examiner here, the workload is spread across the 5 distinct examiners. This lack of examiner concentration means that no single examiner's backlog is likely to create a bottleneck for the university's overall patenting efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.8% |
| BAUER, BRIANNA LEE | 1 | 100.0% | +0.0% |
| MONTGOMERY, ANN Y | 1 | 69.0% | +27.7% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18864008 | 5-PYRIDINE-1H-INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE | ANDERSON, REBECCA L | — |
| 18652809 | SMALL MOLECULE COMPOUNDS TARGETING SRSF6 PROTEIN AND THEIR PREPARATION METHODS AND APPLICATIONS | MCDOWELL, BRIAN E | — |
| 18694439 | INHIBITOR OF RECEPTOR-INTERACTING PROTEIN KINASE 1, AND PREPARATION METHOD AND USE THEREFOR | BAUER, BRIANNA LEE | — |
| 17773492 | METHOD FOR ANCHORING AND MODIFYING NANO-DRUG ON SURFACE OF LIVING CELL | CANELLA, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18864008 | 5-PYRIDINE-1H-INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE | ANDERSON, REBECCA L | — |
| 18652809 | SMALL MOLECULE COMPOUNDS TARGETING SRSF6 PROTEIN AND THEIR PREPARATION METHODS AND APPLICATIONS | MCDOWELL, BRIAN E | — |
| 18570741 | CELLULAR SENSORS BASED ON SURFACE-ENHANCED RAMAN SCATTERING AND APPLICATION THEREOF | MONTGOMERY, ANN Y | — |
| 17773492 | METHOD FOR ANCHORING AND MODIFYING NANO-DRUG ON SURFACE OF LIVING CELL | CANELLA, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1623 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18864008 | 5-PYRIDINE-1H-INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE | ANDERSON, REBECCA L | — | §101§102§112 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18652809 | SMALL MOLECULE COMPOUNDS TARGETING SRSF6 PROTEIN AND THEIR PREPARATION METHODS AND APPLICATIONS | MCDOWELL, BRIAN E | 1624 | §102§112 | Non-Final OA | — | Pending | May 01, 2024 |
| 18694439 | INHIBITOR OF RECEPTOR-INTERACTING PROTEIN KINASE 1, AND PREPARATION METHOD AND USE THEREFOR | BAUER, BRIANNA LEE | 1623 | §103§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18570741 | CELLULAR SENSORS BASED ON SURFACE-ENHANCED RAMAN SCATTERING AND APPLICATION THEREOF | MONTGOMERY, ANN Y | — | §112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 17773492 | METHOD FOR ANCHORING AND MODIFYING NANO-DRUG ON SURFACE OF LIVING CELL | CANELLA, KAREN A | 1643 | §103§112 | Final Rejection | — | Pending | Apr 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial